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Clinical Infectious Diseases
MAJOR ARTICLE
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Background. Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for
C. difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy in participants with characteristics associated with increased
risk for rCDI.
Methods. The analysis population was the modified intent-to-treat population who received bezlotoxumab or placebo (n = 1554)
by risk factors for rCDI that were prespecified in the statistical analysis plan: age ≥65 years, history of CDI, compromised immunity,
severe CDI, and ribotype 027/078/244. The proportion of participants with rCDI in 12 weeks, fecal microbiota transplant procedures,
30-day all cause and CDI-associated hospital readmissions, and mortality at 30 and 90 days after randomization were presented.
Results. The majority of enrolled participants (75.6%) had ≥1 risk factor; these participants were older and a higher proportion
had comorbidities compared with participants with no risk factors. The proportion of placebo participants who experienced rCDI
exceeded 30% for each risk factor compared with 20.9% among those without a risk factor, and the rCDI rate increased with the
number of risk factors (1 risk factor: 31.3%; ≥3 risk factors: 46.1%). Bezlotoxumab reduced rCDI, fecal microbiota transplants, and
CDI-associated 30-day readmissions in participants with risk factors for rCDI.
Conclusions. The risk factors prespecified in the MODIFY statistical analysis plan are appropriate to identify patients at high
risk for rCDI. While participants with ≥3 risk factors had the greatest reduction of rCDI with bezlotoxumab, those with 1 or 2 risk
factors may also benefit.
Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).
Keywords. C. difficile infection; CDI; recurrence; bezlotoxumab.
Clostridium difficile is a gram-positive, anaerobic, spore-forming
bacillus, ubiquitous in nature and able to survive long periods in the
environment. Clostridium difficile infection (CDI) occurs in the gastrointestinal tract of individuals whose normal gut microbiota has
been disrupted, usually by prior antimicrobial use, leading to loss
of colonization resistance and opportunistic infection with C. difficile [1]. Treatment requires specific antibiotic therapy to eliminate
C. difficile from the colon; however, after completing initial antibiotic
therapy with metronidazole or vancomycin, approximately 25% of
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patients have recurrent CDI (rCDI) [2, 3], and approximately 40%
with a first recurrence experience a second recurrence [4]. Certain
host or pathogen factors have been associated with an increased
risk of rCDI or CDI-related adverse outcomes: age ≥65 years [5, 6],
compromised immunity [7], severe CDI [8, 9], prior CDI episode(s) [4], and infection with the BI/NAP1/027 strain [5, 10–12].
As the incidence of rCDI is rising, there is an unmet need for therapies to prevent rCDI [13].
In 2 global, phase 3 trials (monocolonal antibodies for C. difficile therapy [MODIFY] I and MODIFY II), bezlotoxumab,
a human monoclonal antibody against C. difficile toxin B,
demonstrated significant reductions in CDI recurrence compared with placesbo (17% vs 28% in MODIFY I and 16% vs
26% in MODIFY II; P < .001) in adults receiving antibiotic
treatment for primary CDI or rCDI [14]. To identify the population that may benefit most from bezlotoxumab treatment,
the current analysis pooled data from the MODIFY studies
to assess the efficacy of bezlotoxumab in participants with the
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Bezlotoxumab for Prevention of Recurrent Clostridium
difficile Infection in Patients at Increased Risk for
Recurrence

characteristics listed above that are associated with increased
risk for rCDI.
METHODS

Population, Endpoints, and Statistical Methods

The analysis population was the modified intent-to-treat (mITT)
population (defined as all randomly assigned participants who
received study infusion, had a positive toxigenic C. difficile–
positive stool test, and received standard-of-care [SOC] therapy
within 1 day of receiving treatment) in the pooled dataset from
MODIFY I and MODIFY II, who received bezlotoxumab or placebo, and was further categorized based on known risk factors for
rCDI or CDI-related adverse outcomes that had been prespecified at the time of protocol development in the statistical analysis
plan: age ≥65 years, history of CDI in the previous 6 months,
compromised immunity, severe CDI (Zar score ≥2 points) at time
of randomization, and isolation of a strain associated with poor
outcomes (ribotypes 027, 078, or 244). Use of concomitant systemic antibiotics, although a known risk factor for rCDI [15], was
not prespecified as a risk factor for subgroup analysis because only
risk factors present at the time of randomization were included.
Endpoints included proportion of participants who achieved
initial clinical cure, where initial clinical cure is defined as no
diarrhea for 2 consecutive days after completion of antibiotic
therapy administered for ≤16 calendar days; proportion of participants with rCDI, where rCDI is defined as the development
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RESULTS
Study Population

There were 1554 participants (bezlotoxumab: 781; placebo:
773) included in the mITT population in both studies. The
majority of participants (75.6% [1175/1554]: 592 bezlotoxumab, 583 placebo) had at least 1 prespecified risk factor for
rCDI or CDI-related adverse outcomes: Approximately 36%
had a single risk factor, approximately 27% had 2 risk factors,
and approximately 12% had ≥3 risk factors (Table 1). In the
group of participants with at least 1 risk factor, 497 (84.0%) and
482 (82.7%) participants remained in the study through week 12
in the bezlotoxumab and placebo groups, respectively. A higher
proportion of participants with no risk factors completed the
study (91.5% bezlotoxumab, 86.8% placebo) compared with
participants with at least 1 risk factor. Reasons for discontinuation by treatment group and by risk category are summarized
in Supplementary Table 1. The proportion of participants who
prematurely discontinued the study due to death was higher in
participants with at least 1 risk factor (7.8% bezlotoxumab, 8.6%
placebo) compared with the proportion with no risk factors
(3.2% for both bezlotoxumab and placebo).
Demographic and clinical characteristics were similar
between the bezlotoxumab and placebo groups when comparing within each of the 2 risk categories (Table 1). The participants with at least 1 risk factor were older and a higher
percentage had a Charlson index ≥3, had renal impairment, had
hypoalbuminemia, and received vancomycin or fidaxomicin as
the SOC antibiotic (Table 1) compared with the group of participants with no risk factors.
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MODIFY I (NCT01241552) and II (NCT01513239) were independent, randomized, double-blind, placebo-controlled, multicenter phase 3 trials with nearly identical design, conducted
from November 2011 through May 2015 at 322 sites in 30 countries. The protocols and all amendments were approved by the
institutional review board or independent ethics committee
at each study center. Each study was conducted in accordance
with Good Clinical Practice Guidelines and the Declaration of
Helsinki. Written informed consent was obtained before study
procedures were performed.
Adults with primary or rCDI receiving antibacterial treatment (determined by the treating physician) for CDI were
enrolled. Eligibility criteria were previously described [14].
CDI was defined as diarrhea (≥3 unformed bowel movements
in 24 hours) associated with a positive stool test for toxigenic
C. difficile or its toxin(s). Participants included in this subgroup
analysis received either 1 dose of bezlotoxumab 10 mg/kg or
placebo (0.9% saline) during antibacterial drug treatment for
CDI. Randomization was stratified by oral antibacterial treatment (metronidazole, vancomycin, or fidaxomicin) and hospitalization status (inpatient or outpatient). The number of
unformed bowel movements was recorded by participants daily
through 12 weeks and new episodes of diarrhea were monitored
via scheduled phone contacts between visits.

of a new episode of diarrhea associated with a positive stool test
for toxigenic C. difficile within 12 weeks following study medication infusion assessed in mITT participants who achieved
initial clinical cure (clinical cure population); proportion of
participants who received a fecal microbiota transplant (FMT),
proportion of participants who experienced 30-day all cause
and CDI-associated hospital readmissions as defined previously
[16] in mITT participants who were in a healthcare facility at
the time of randomization; and proportion of participants who
had died at 30 and 60 days after randomization.
Observed rates for rCDI along with differences between the
bezlotoxumab and placebo groups and their 95% confidence
intervals (CIs) were presented by prespecified risk factor subgroup and by combinations of risk factors. The 95% CIs were
obtained using the Miettinen and Nurminen method [17]. The
nonparametric Kaplan-Meier method was used to estimate
the distribution of time to CDI recurrence for each subgroup
within each treatment group. Observed rates were presented
for those requiring FMT during the 12-week follow-up period,
30-day all-cause and CDI-associated hospital readmissions, and
mortality at 30 and 60 days after randomization.

Table 1.

Baseline Demographics, Clinical Characteristics, and Predefined Risk Factors, Modified Intent-to-Treat Population
Bezlotoxumab (N = 781)

Placebo (N = 773)

No Risk Factors

≥1 Risk Factor

No Risk Factors

≥1 Risk Factor

n = 189

n = 592

n = 190

n = 583
68.5 (15.6)

Age, y
  Mean (SD)

46.6 (12.8)

66.7 (16.7)

48.2 (13.2)

  Median

51

69

52

71

  Range

20–64

18–100

19–64

18–98

  18–49

87 (46.0)

87 (14.7)

81 (42.6)

72 (12.3)

  50–64

102 (54.0)

115 (19.4)

109 (57.4)

106 (18.2)

  65–79

NA

250 (42.2)

NA

253 (43.4)

  ≥80

NA

140 (23.6)

NA

152 (26.1)

117 (61.9)

325 (54.9)

118 (62.1)

331 (56.8)

Female sex
SOC antibiotic

127 (67.2)

252 (42.6)

124 (65.3)

250 (42.9)

Vancomycin

Metronidazole

59 (31.2)

313 (52.9)

63 (33.2)

310 (53.2)

Fidaxomicin

3 (1.6)

27 (4.6)

3 (1.6)

23 (3.9)

Clinical characteristics
Age ≥65 ya

NA

390 (65.9)

NA

405 (69.5)

Primary CDI

146 (77.2)

278 (47.0)

145 (76.3)

255 (43.7)

≥1 CDI episodes in past 6 moa

NA

216 (36.5)

NA

219 (37.6)

1 previous CDI episode ever

6 (3.2)

144 (24.3)

6 (3.2)

126 (21.6)

≥2 previous CDI episodes ever

4 (2.1)

96 (16.5)

4 (2.2)

122 (21.4)

Severe CDI (Zar score ≥2)a,b

NA

122 (20.6)

NA

125 (21.4)

Immunocompromiseda,c

NA

178 (30.1)

NA

Inpatient at time of randomization

95 (50.3)

Antibiotic used during SOC

45 (23.8)

Antibiotic used after SOC

38 (20.1)

Charlson index ≥3

48 (25.4)

Renal impairmente
Hepatic impairmentf
Albumin <2.5 g/dL

435 (73.5)

153 (26.2)

98 (51.6)

422 (72.4)

201 (34.0)

58 (30.5)

218 (37.4)

208 (35.1)

45 (23.7)

179 (30.7)

271 (45.8)

43 (22.6)

260 (44.6)

12 (6.3)

111 (18.8)

20 (10.5)

90 (15.4)

12 (6.3)

37 (6.3)

9 (4.7)

35 (6.0)

13 (6.9)

88 (14.9)

9 (4.7)

94 (16.1)
372 (63.8)

Clostridium difficile straing
Participants with a positive culture

112 (59.3)

378 (63.9)

114 (60.0)

Ribotype 027, 078, or 244a

NA

102 (27.0)

NA

115 (30.9)

Ribotype 027

NA

89 (23.5)

NA

100 (26.9)

No. of prespecified risk factors
0

189 (24.2)

1

283 (36.2)

190 (24.6)
274 (35.4)

2

220 (28.2)

208 (26.9)

3

73 (9.3)

82 (10.6)

4

14 (1.8)

14 (2.0)

5

2 (0.3)

5 (0.6)

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CDI, Clostridium difficile infection; NA, not analyzed; SD, standard deviation; SOC, standard of care.
a

Prespecified risk factor.

b

Based on the following: (1) age >60 years (1 point); (2) body temperature >38.3°C (>101°F) (1 point); (3) albumin level <2.5 g/dL (1 point); (4) peripheral white blood cell count >15 000 cells/µL
within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care unit (2 points).
c

Defined on the basis of a participant’s medical history or use of immunosuppressive therapy.

d

Systemic antibiotic other than SOC antibiotic given to treat CDI.

e

Renal impairment defined as serum creatinine ≥1.5 mg/dL.

f

Hepatic impairment defined by ≥2 of the following: (1) albumin ≤3.1 g/dL; (2) alanine aminotransferase ≥2 times the upper limit of normal (ULN); (3) total bilirubin ≥1.3 times the ULN; or (4)
mild, moderate, or severe liver disease (as reported on the Charlson index).
g

Denominator is participants in the modified intent-to-treat population with a positive culture.

Initial Clinical Cure

Treatment with bezlotoxumab did not impact the proportion of
participants with initial clinical cure of the episode under treatment with SOC antibiotics. Initial clinical cure rates were similar in

the bezlotoxumab and placebo groups in participants with at least
1 risk factor (79.6% vs 80.3%, respectively; difference, –0.7 [95%
CI, –5.3 to 3.9]) and in the participants with no risk factors (81.5%
vs 80.5%, respectively; difference, 1.0 [95% CI, –7.0 to 8.9]).
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Characteristic
Demographics

CDI Recurrence

Parcipants With CDI
Recurrence, %

Parcipants With CDI
Recurrence, %

factors, respectively (95% CIs excluded 0 for all comparisons;
Figure 1B). In contrast, among participants with no risk factors, the proportion of participants with CDI recurrences
was similar between treatment groups (18.8% bezlotoxumab
vs 20.9% placebo; difference, –2.1 [95% CI, –11.1 to 6.9];
Figure 1B).
The proportion of participants experiencing rCDI in clinically relevant subpopulations is shown in Figure 2. In the
placebo-treated participants with a single risk factor, the
rate of rCDI ranged from 29.8% in participants experiencing
primary CDI who had at least 1 risk factor, to 54.3% in participants who had at least 1 prior episode of CDI and were
immunocompromised.
In all subgroups assessed, including participants with primary CDI (with or without any prespecified risk factors),
rCDI rates were lower in participants treated with bezlotoxumab compared with those treated with placebo (Figure 2).
The absolute difference in the rate of rCDI between the bezlotoxumab and placebo groups was highest in participants
who had both a history of CDI and severe CDI (–35.7% [95%

Figure 1. A, Proportion of participants with Clostridium difficile infection (CDI) recurrence, by prespecified risk factor. Each subgroup includes all participants with the
risk factor (ie, those with only 1 risk factor and those with the specified risk factor and ≥1 additional risk factor). B, Proportion of participants with CDI recurrence, by
number of prespecified risk factors (clinical cure population). Difference and 95% confidence intervals, shown above bars, were based on the Miettinen and Nurminen
method. Prespecified risk factors include age ≥65 years, history of CDI in the previous 6 months, immunocompromised, severe CDI, and having a strain associated with
poor outcomes of CDI (ribotype 027, 078, or 244). †CDI history in the previous 6 months. ‡Defined on the basis of a subject’s medical history or use of immunosuppressive
therapy. §Based on the Zar score, scored as (1) age >60 years (1 point); (2) body temperature >38.3°C (>101°F) (1 point); (3) albumin level <2.5 g/dL (1 point); (4) peripheral
white blood cell count >15 000 cells/µL within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care
unit (2 points). ॥Denominator is participants in the modified intent-to-treat population with a positive culture. Abbreviations: Bezlo, bezlotoxumab; CDI, Clostridium difficile
infection; Hx, history; RT, ribotype.
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Among participants who received placebo and achieved initial
clinical cure, the proportion of participants who experienced
rCDI during the 12-week follow-up period exceeded 30% for
each of the 5 prespecified risk factors (Figure 1A). The proportion of participants who experienced a recurrence in the placebo group was 20.9% among those without a risk factor and
increased with the number of risk factors (Figure 1B), 31.3% for
participants with 1 risk factor, and 46.1% in participants with at
least 3 risk factors.
Bezlotoxumab reduced the rate of rCDI compared with
placebo among participants with each of the 5 prespecified
risk factors, and the 95% CIs excluded 0 for all comparisons except the ribotype 027/078/244 subgroup (Figure 1A).
Among participants who had ≥1 risk factor, treatment with
bezlotoxumab reduced CDI recurrences compared with
placebo (21.2% vs 37.2%, respectively; difference, –15.9
[95% CI, –21.6 to –10.2]; Figure 1B). The absolute reduction was –14.2%, –14.2%, and –24.8% (relative reduction:
–45.3%, –34.5%, and –53.9%) for those with 1, 2, and ≥3 risk

CI, –60.5% to –2.8%]) and was lowest in patients who were
<65 years of age (–4.4% [95% CI, –11.2% to 2.3%]). Of note,
the 95% CIs crossed 0 for some of these subgroups due to
small differences (eg, younger age) or due to the limited size
of the subgroup (eg, history of CDI and infected with ribotype
027/078/244).
Most CDI recurrences occurred within 4 weeks of study infusion (range, 63%–78% across subgroups; Figure 3). There were
differences in the rate of rCDI at week 4 between participants
with ≥1 risk factor who received placebo compared with participants with ≥1 risk factor who received bezlotoxumab, and
these differences were maintained through week 12. In participants with no risk factors who received either placebo or bezlotoxumab, the time-to-event curve was similar to the curve for
the bezlotoxumab group with ≥1 risk factor (Figure 3).
Other Outcomes

The proportion of participants who (1) had an FMT during the
90-day follow-up period, (2) were readmitted to the hospital
within 30 days of discharge, and (3) died within 30 or 90 days of

study entry was higher in participants with at least 1 risk factor for
rCDI compared with those with no risk factors (Table 2). Among
participants in the placebo group, there were more FMTs and more
CDI-associated 30-day hospital readmissions compared with bezlotoxumab participants in both risk factor categories (Table 2).
DISCUSSION

Individual characteristics such as age ≥65 years [5, 18], compromised immunity [7], severe CDI [8, 9], history of CDI [4],
and infection with the BI/NAP1/027 strain [5, 10–12] have
been shown to increase a patient’s risk for rCDI and/or CDIrelated adverse outcomes. However, previous studies have not
investigated the impact of multiple risk factors on these outcomes. The current analysis included data from 2 large, prospective, randomized, placebo-controlled trials that enrolled
participants with multiple risk factors [14]. Approximately
75% of the participants enrolled in the MODIFY trials had at
least 1 of 5 prespecified risk factors, and 40% had at least 2
risk factors. Based on the data from the group of participants
who received placebo, this post hoc analysis confirmed that
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Figure 2. Clostridium difficile infection (CDI) recurrence rates by risk factor subgroup (clinical cure population). Unless otherwise specified, each subgroup includes all
patients with the risk factor(s) (ie, those with only the specified risk factor[s] and those with the specified risk factor[s] and ≥1 additional risk factor). Abbreviations: CDI
Hx, Clostridium difficile infection history in the previous 6 months; CI, confidence interval.

presence of at least 1 of the 5 prespecified risk factors increased
the risk for rCDI, 30-day and 90-day mortality, 30-day CDIassociated hospital readmissions, and need for FMT compared
with having none of these 5 risk factors, with the exception
of hypervirulent strains. Furthermore, as the number of risk
factors increased, the proportion of placebo participants with
Table 2.

rCDI also increased and was greatest in participants with at
least 3 risk factors.
The most frequently cited risk factor for rCDI is having had
a previous episode. The rate of rCDI in participants receiving
placebo in the MODIFY trials who were experiencing their first
episode was 26.5%. The rate climbed to 41.3% in participants

Other Outcomes

Outcome

Bezlotoxumab

a

FMT during follow-up

30-day readmissionsb
All-cause
CDI-associated
Mortalityc

Placebo

No Risk Factors

≥1 Risk Factor

No Risk Factors

≥1 Risk Factor

n = 189

n = 592

n = 190

n = 583

0 (0.0)

7 (1.2)

5 (2.6)

18 (3.1)

n = 95

n = 435

n = 98

n = 422

20 (21.1)

103 (23.7)

20 (20.4)

120 (28.4)

2 (2.1)

25 (5.7)

4 (4.1)

54 (12.8)

n = 189

n = 597

n = 192

n = 589

30-day

2 (1.1)

25 (4.2)

3 (1.6)

24 (4.1)

90-day

6 (3.2)

48 (8.0)

6 (3.1)

53 (9.0)

Abbreviations: CDI, Clostridium difficile infection; FMT, fecal microbiota transplant.
a

Modified intent-to-treat (mITT) population.

b

mITT population who were inpatients at the time of randomization.

c

All patients as treated population.
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Figure 3. Kaplan-Meier plot of time to Clostridium difficile infection (CDI) recurrence over 12 weeks of follow-up by high-risk-factor subgroups (modified intent-to-treat
population). The start date of CDI recurrence was the first date of the new episode of diarrhea. For subjects who were lost to follow-up prior to a CDI recurrence, time to event
was right-censored at the date of the last stool record. Participants who completed the 12-week follow-up period without documented CDI recurrence were censored at the
date of the last completed stool record. For participants who failed to achieve a clinical cure for the baseline CDI episode, time to event was right-censored at the date of
infusion of study medication (day 1). Abbreviations: Bezlo, bezlotoxumab; CDI, Clostridium difficile infection; CI, confidence interval.

procedure; additional research is needed to confirm these
results. Bezlotoxumab also reduced the number of CDI-related
hospital readmissions in participants with at least 1 risk factor
compared with the placebo group (difference, –7.1%). These
results are consistent with a previous analysis of bezlotoxumab
data demonstrating a reduction in 30-day CDI-associated hospital readmissions in those aged ≥65 years and with severe CDI
[16]. Although the presence of risk factors increased 30- and
90-day mortality rates, the relatively low rates observed in this
study vs those observed in observational studies of patients with
CDI [22, 23] may be in part due to the study entry requirement
for participants to survive at least 72 hours, potentially biasing
the results to the null when assessing differences in mortality.
There were limitations to this analysis. Although the clinical
characteristics that were prespecified in the protocol are known
risk factors for rCDI or CDI-related adverse outcomes, there
are other risk factors for rCDI that were not included. Results
may be different if other risk factors are considered. Although
there were a large number of participants with at least 1 risk factor included (n = 1175), and the baseline characteristics among
these participants across treatment groups were well balanced,
many of the analyses presented here were conducted post hoc
and the study was not powered for statistical significance for
subgroup analyses. Therefore, the results should be considered
preliminary.
In conclusion, these results demonstrate that the risk factors prespecified in the MODIFY statistical analysis plan are
appropriate to identify patients who are at high risk for rCDI.
While participants with at least 3 risk factors appear to have the
greatest risk reduction with bezlotoxumab, those with only 1
of the risk factors may also benefit from bezlotoxumab. These
observations may help direct clinicians to patients who are most
likely to benefit from bezlotoxumab.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the authors,
so questions or comments should be addressed to the corresponding author.
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who had 1 prior episode and was 51.5% in participants with
≥2 prior episodes. These rates are comparable with previously
reported rates [4]. Of note, at least 50% of placebo-treated participants who had both a recent history of CDI and at least 1
other risk factor experienced rCDI within 12 weeks of infusion.
While participants with primary CDI had lower rates of rCDI,
the rate was approximately 30% in the primary CDI subgroup
that had at least 1 risk factor, suggesting that there are some
patients with primary CDI who may be considered to be at high
risk for rCDI.
Older age (≥65 years) has been characterized as a risk factor
in almost all studies reporting on risk factors for rCDI. While
it is generally assumed that the higher rate in older patients is
likely because they have other risk factors that contribute to
the higher rate of rCDI compared with younger patients, in
this analysis, almost one-third of placebo-treated participants
with age ≥65 years as their sole risk factor experienced rCDI.
As expected, the proportion of older placebo participants who
experienced rCDI and had an additional risk factor was higher
than those ≥65 years as their only risk factor (range, 33.3%–
48.3%). A lower rate of rCDI was observed in younger participants (age <65 years, 26.4%). However, the rate exceeded 30%
in the subgroup of younger participants who had at least 1 of the
4 other risk factors.
A major strength of this analysis was that it identified patients
who are likely to benefit from treatment with bezlotoxumab. In
participants with at least 1 risk factor, treatment with bezlotoxumab reduced the proportion of participants with rCDI over
a 12-week period compared with placebo (absolute reduction
16%, relative reduction 43%); a larger reduction was observed
in participants with ≥3 risk factors (absolute reduction 24.8%,
relative reduction 54%).
The proportion of participants with no risk factors who experienced rCDI in the MODIFY trials was relatively low in both
treatment groups (~20%). In general, participants without 1 of
these known risk factors for rCDI at the time of diagnosis are not
likely to benefit from bezlotoxumab. It is important to note, however, that participants with primary CDI and without one of the
prespecified risk factors may have other risk factors such as renal
impairment [19], inflammatory bowel disease [20], or concomitant antibiotic use [21] that were not included in this analysis and
could also benefit from bezlotoxumab therapy for prevention of
a future recurrence. Ongoing analyses may identify other at-risk
populations that will benefit from bezlotoxumab treatment.
Results for other post hoc endpoints are supportive of the
benefit of bezlotoxumab in patients at high risk for rCDI or
CDI-related adverse outcomes. Fewer bezlotoxumab-treated
participants received an FMT during the 12-week follow-up
period compared with the placebo-treated participants. While
this observation is encouraging, it should be noted that FMT
procedures were performed at only 17 trial sites, which reflects
that the study was not limited to sites that have access to this
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